These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 26562759)

  • 1. Long-Range Communication Network in the Type 1B Bone Morphogenetic Protein Receptor.
    Evangelista W; Yeh LC; Gmyrek A; Lee JC; Lee JC
    Biochemistry; 2015 Dec; 54(48):7079-88. PubMed ID: 26562759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure analysis of bone morphogenetic protein-2 type I receptor complexes reveals a mechanism of receptor inactivation in juvenile polyposis syndrome.
    Kotzsch A; Nickel J; Seher A; Heinecke K; van Geersdaele L; Herrmann T; Sebald W; Mueller TD
    J Biol Chem; 2008 Feb; 283(9):5876-87. PubMed ID: 18160401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single residue of GDF-5 defines binding specificity to BMP receptor IB.
    Nickel J; Kotzsch A; Sebald W; Mueller TD
    J Mol Biol; 2005 Jun; 349(5):933-47. PubMed ID: 15890363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlating interfacial water dynamics with protein-protein interaction in complex of GDF-5 and BMPRI receptors.
    Kausar T; Nayeem SM
    Biophys Chem; 2018 Sep; 240():50-62. PubMed ID: 29890403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor.
    Weber D; Kotzsch A; Nickel J; Harth S; Seher A; Mueller U; Sebald W; Mueller TD
    BMC Struct Biol; 2007 Feb; 7():6. PubMed ID: 17295905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystal structure analysis reveals a spring-loaded latch as molecular mechanism for GDF-5-type I receptor specificity.
    Kotzsch A; Nickel J; Seher A; Sebald W; Müller TD
    EMBO J; 2009 Apr; 28(7):937-47. PubMed ID: 19229295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virtual screening and selection of drug-like compounds to block noggin interaction with bone morphogenetic proteins.
    Ahmed S; Metpally RP; Sangadala S; Reddy BV
    J Mol Graph Model; 2010 Apr; 28(7):670-82. PubMed ID: 20137990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Receptor oligomerization and beyond: a case study in bone morphogenetic proteins.
    Heinecke K; Seher A; Schmitz W; Mueller TD; Sebald W; Nickel J
    BMC Biol; 2009 Sep; 7():59. PubMed ID: 19735544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the ligand-binding site of the BMP type IA receptor for BMP-4.
    Hatta T; Konishi H; Katoh E; Natsume T; Ueno N; Kobayashi Y; Yamazaki T
    Biopolymers; 2000; 55(5):399-406. PubMed ID: 11241215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type I receptor binding of bone morphogenetic protein 6 is dependent on N-glycosylation of the ligand.
    Saremba S; Nickel J; Seher A; Kotzsch A; Sebald W; Mueller TD
    FEBS J; 2008 Jan; 275(1):172-83. PubMed ID: 18070108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of heparin binding sites in bone morphogenetic proteins (BMPs).
    Gandhi NS; Mancera RL
    Biochim Biophys Acta; 2012 Dec; 1824(12):1374-81. PubMed ID: 22824487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-throughput measurements of bone morphogenetic protein/bone morphogenetic protein receptor interactions using biolayer interferometry.
    Khodr V; Machillot P; Migliorini E; Reiser JB; Picart C
    Biointerphases; 2021 Jun; 16(3):031001. PubMed ID: 34241280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GDF-5 can act as a context-dependent BMP-2 antagonist.
    Klammert U; Mueller TD; Hellmann TV; Wuerzler KK; Kotzsch A; Schliermann A; Schmitz W; Kuebler AC; Sebald W; Nickel J
    BMC Biol; 2015 Sep; 13():77. PubMed ID: 26385096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of ligand-binding properties of the human BMP type II receptor extracellular domain.
    Yin H; Yeh LC; Hinck AP; Lee JC
    J Mol Biol; 2008 Apr; 378(1):191-203. PubMed ID: 18342887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activating and deactivating mutations in the receptor interaction site of GDF5 cause symphalangism or brachydactyly type A2.
    Seemann P; Schwappacher R; Kjaer KW; Krakow D; Lehmann K; Dawson K; Stricker S; Pohl J; Plöger F; Staub E; Nickel J; Sebald W; Knaus P; Mundlos S
    J Clin Invest; 2005 Sep; 115(9):2373-81. PubMed ID: 16127465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of the Alk1 extracellular domain and characterization of its bone morphogenetic protein (BMP) binding properties.
    Mahlawat P; Ilangovan U; Biswas T; Sun LZ; Hinck AP
    Biochemistry; 2012 Aug; 51(32):6328-41. PubMed ID: 22799562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of BMP receptor synthesis by antisense oligonucleotides attenuates OP-1 action in primary cultures of fetal rat calvaria cells.
    Yeh LC; Betchel KP; Lee JC
    J Bone Miner Res; 1998 Dec; 13(12):1870-9. PubMed ID: 9844105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II.
    Kirsch T; Nickel J; Sebald W
    EMBO J; 2000 Jul; 19(13):3314-24. PubMed ID: 10880444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure of the ternary signaling complex of a TGF-beta superfamily member.
    Allendorph GP; Vale WW; Choe S
    Proc Natl Acad Sci U S A; 2006 May; 103(20):7643-8. PubMed ID: 16672363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal structure of the BMP-2-BRIA ectodomain complex.
    Kirsch T; Sebald W; Dreyer MK
    Nat Struct Biol; 2000 Jun; 7(6):492-6. PubMed ID: 10881198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.